AKT1 and nasopharyngeal carcinoma: An accumulating evidences indicated that targeting PI3K/AKT/mTOR pathway by Rapamycin inhibits NPC cell development in vitro, suggesting that a potential application of Rapamycin for the clinical treatment of NPC [47].